Antagonist screening assay for ICOS/ICOS-L axis

InvivoGen offers a cellular assay specifically designed for screening antibody-, Fc-fusion protein-, or small-molecule antagonists of the ICOS/ICOS-L immune checkpoint (IC) axis. This assay is comprised of:

PPrinciple of ICOS/ICOS-L cellular assay
Principle of ICOS/ICOS-L cellular assay
(click to enlarge)

InvivoGen also offers:

• Agonist screening assay for ICOS/ICOS-L axis
• hICOS-L-Fc fusion protein
• hICOS-Fc fusion protein

Jurkat-Lucia™ hICOS: Reporter T cells
Raji-hICOS-L: Antigen-presenting cells (APCs)

These paired cell lines allow the mimicking of the immune synapse between T cells and APCs through the interaction of cell surface molecules delivering T-cell activation signals.

Inducible Co-stimulator (ICOS, CD278) is an immunostimulatory IC and a member of the CD28 superfamily. Expression of ICOS is rapidly induced in CD4 and CD8 T cells upon their activation, whereas its ligand ICOS-L (CD275), is mostly expressed by APCs [1].

More details

Assay principle:

This assay relies on the co-culture of Jurkat-Lucia™ hICOS and Raji-hICOS-L cells:
– Jurkat-Lucia™-ICOS cells express a hICOS-CD3ζ fusion protein along with the Lucia luciferase reporter gene under the control of an ISG54 minimal promoter fused to six NFAT response elements. CD3ζ is a key component of the T-cell receptor (TCR) and CD3 complex that triggers TCR downstream signaling.
– Raji-hICOS-L cells express the ICOS-L activating IC ligand.
In the presence of a potent ICOS or ICOS-L antagonist, the ICOS-CD3ζ-mediated activation is blocked and there is no Lucia production. Activation of the reporter T cells can be readily measured using QUANTI-Luc™ 4 Lucia/Gaussia detection reagent (see Figures).

T-cell key features:

Stable hICOS-CD3ζ expression
NFAT-inducible Lucia luciferase reporter activity

APC key features:

Stable hICOS-L overexpression

InvivoGen also offers Jurkat-Lucia™ hICOS cells without Raji-hICOS-L cells to measure the potency of agonists of the ICOS/ICOS-L axis.

Read our review on Immune Checkpoint Blockade

Learn more about Immune Checkpoint Antibodies.

Reference:

1. Amatore, F. et al. 2020. Role of ICOS in cancer immunotherapy. Expert Opin Biol Ther 20, 141-150.

Clear allRefined by

Products4

Research Fields1

5 Search results: raji-hicos